Thursday, September 24, 2026
Privacy-First Edition
Back to NNN
Health

Chinese drug Loberamisal extends stroke treatment window from 6 hours to 2 days

Large-scale clinical trial with nearly 1,000 patients from 32 hospitals delivers 13 per cent leap in recovery over standard care alone

3-MIN READ3-MINShi HuangPublished: 2:29pm, 24 Sep 2026Chinese medical scientists have shattered the brief window of time available to limit stroke damage, effectively shielding injured brain cells and dramatically improving the odds of a full recovery.Brain cells start dying within minutes of a clot blocking an artery, leading to facial droop, affected speech and in severe cases, paralysis or death. Emergency treatments, such as clot-busting drugs or surgery, must be given within a maximum of six hours.

According to a study published by the top-tier Journal of the American Medical Association on September 10, clinical trials of the drug Loberamisal found it was possible to expand the time available to 48 hours.

The large-scale multicentre phase 3 trial found that 70 per cent of patients who received Loberamisal intravenously within two days of a stroke regained complete functional independence – a leap of 13 percentage points over standard care alone.

Read original at South China Morning Post

The Perspectives

0 verified voices · Three viewpoints · Real discourse

Left
0
Be the first to share a left perspective
Center
0
Be the first to share a center perspective
Right
0
Be the first to share a right perspective

Related Stories